Invesco Ltd. Sells 1,323,514 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Invesco Ltd. trimmed its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 10.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,296,255 shares of the biotechnology company's stock after selling 1,323,514 shares during the quarter. Invesco Ltd. owned about 4.78% of ADMA Biologics worth $193,731,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ADMA. Perpetual Ltd bought a new stake in shares of ADMA Biologics during the 4th quarter valued at approximately $62,300,000. Lord Abbett & CO. LLC acquired a new stake in shares of ADMA Biologics during the 3rd quarter valued at $61,858,000. Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. Raymond James Financial Inc. acquired a new position in ADMA Biologics in the 4th quarter worth about $19,076,000. Finally, Principal Financial Group Inc. increased its holdings in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after purchasing an additional 1,059,394 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Up 5.9 %

Shares of NASDAQ:ADMA traded up $1.24 during mid-day trading on Tuesday, reaching $22.15. 7,152,085 shares of the company's stock were exchanged, compared to its average volume of 3,589,965. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a twelve month low of $5.91 and a twelve month high of $23.64. The firm has a market capitalization of $5.24 billion, a price-to-earnings ratio of 79.11 and a beta of 0.53. The business's fifty day moving average price is $17.86 and its 200-day moving average price is $18.16.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.